osilodrostat + cabergoline

Osilodrostat + cabergoline is a combination therapy being investigated for the treatment of Cushing's disease. Osilodrostat is a potent oral inhibitor of 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol synthesis in the adrenal cortex. Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits the secretion of adrenocorticotropic hormone (ACTH) from pituitary adenomas. This combination strategy aims to achieve biochemical control of hypercortisolism through complementary mechanisms: central suppression of ACTH (cabergoline) and peripheral blockade of cortisol production (osilodrostat). The University of Basrah is conducting clinical research to evaluate if this pairing can improve efficacy, reduce dose requirements for osilodrostat, and mitigate side effects such as mineralocorticoid precursor accumulation and hyperandrogenism.